[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

EA033386B1 - Рекомбинантные иммуногенные полипептиды стеблевого домена гемагглютинина вируса гриппа а и их применение - Google Patents

Рекомбинантные иммуногенные полипептиды стеблевого домена гемагглютинина вируса гриппа а и их применение

Info

Publication number
EA033386B1
EA033386B1 EA201491051A EA201491051A EA033386B1 EA 033386 B1 EA033386 B1 EA 033386B1 EA 201491051 A EA201491051 A EA 201491051A EA 201491051 A EA201491051 A EA 201491051A EA 033386 B1 EA033386 B1 EA 033386B1
Authority
EA
Eurasian Patent Office
Prior art keywords
influenza
virus hemagglutinin
polypeptides
stem domain
recombinant immunogenic
Prior art date
Application number
EA201491051A
Other languages
English (en)
Other versions
EA201491051A1 (ru
Inventor
Jan Wilem Meijberg
Antonietta Impagliazzo
Ronald Vogels
Robert Heinz Edward Friesen
Philippe Alard
Stefan Loverix
Katarina Radosevic
Original Assignee
Janssen Vaccines & Prevention Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Vaccines & Prevention Bv filed Critical Janssen Vaccines & Prevention Bv
Publication of EA201491051A1 publication Critical patent/EA201491051A1/ru
Publication of EA033386B1 publication Critical patent/EA033386B1/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • C07K16/1018—Orthomyxoviridae, e.g. influenza virus
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5258—Virus-like particles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55522—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/57—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2
    • A61K2039/575—Medicinal preparations containing antigens or antibodies characterised by the type of response, e.g. Th1, Th2 humoral response
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/20—Fusion polypeptide containing a tag with affinity for a non-protein ligand
    • C07K2319/21—Fusion polypeptide containing a tag with affinity for a non-protein ligand containing a His-tag
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/35—Fusion polypeptide containing a fusion for enhanced stability/folding during expression, e.g. fusions with chaperones or thioredoxin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/40—Fusion polypeptide containing a tag for immunodetection, or an epitope for immunisation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/50—Fusion polypeptide containing protease site
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/73—Fusion polypeptide containing domain for protein-protein interaction containing coiled-coiled motif (leucine zippers)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16151—Methods of production or purification of viral material
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16171—Demonstrated in vivo effect

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pulmonology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Изобретение относится к рекомбинантным иммуногенным полипептидам стеблевого домена гемагглютинина вируса гриппа A, содержащим (a) домен HA1 гемагглютинина гриппа, который включает N-терминальный сегмент HA1, ковалентно связанный с помощью связывающей последовательности из 0-10 аминокислотных остатков с C-терминальным сегментом HA1, и (b) домен HA2 гемагглютинина гриппа, который включает одну или несколько аминокислотных замен. Изобретение также относится к нуклеиновым кислотам, кодирующим заявленные полипептиды, композициям, содержащим заявленные полипептиды и/или нуклеиновые кислоты, а также к их применению в качестве лекарственного средства против гриппа.
EA201491051A 2011-11-28 2012-11-27 Рекомбинантные иммуногенные полипептиды стеблевого домена гемагглютинина вируса гриппа а и их применение EA033386B1 (ru)

Applications Claiming Priority (7)

Application Number Priority Date Filing Date Title
US201161564086P 2011-11-28 2011-11-28
US201161564198P 2011-11-28 2011-11-28
EP11191003 2011-11-28
EP11191009 2011-11-28
EP12166268 2012-05-01
US201261720281P 2012-10-30 2012-10-30
PCT/EP2012/073706 WO2013079473A1 (en) 2011-11-28 2012-11-27 Influenza virus vaccines and uses thereof

Publications (2)

Publication Number Publication Date
EA201491051A1 EA201491051A1 (ru) 2015-04-30
EA033386B1 true EA033386B1 (ru) 2019-10-31

Family

ID=48534691

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201491051A EA033386B1 (ru) 2011-11-28 2012-11-27 Рекомбинантные иммуногенные полипептиды стеблевого домена гемагглютинина вируса гриппа а и их применение

Country Status (20)

Country Link
US (3) US9452211B2 (ru)
EP (2) EP2785372B1 (ru)
JP (1) JP6294828B2 (ru)
KR (1) KR101983989B1 (ru)
CN (1) CN104066446B (ru)
AR (1) AR089005A1 (ru)
AU (1) AU2012343981B2 (ru)
BR (1) BR112014012681A8 (ru)
CA (1) CA2857087C (ru)
EA (1) EA033386B1 (ru)
HK (1) HK1199211A1 (ru)
IL (1) IL232780A (ru)
IN (1) IN2014CN04742A (ru)
MX (1) MX357009B (ru)
MY (1) MY170927A (ru)
PH (1) PH12014501118A1 (ru)
SG (1) SG11201402633UA (ru)
TW (1) TWI618715B (ru)
WO (1) WO2013079473A1 (ru)
ZA (1) ZA201404797B (ru)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010117786A1 (en) 2009-03-30 2010-10-14 Mount Sinai School Of Medicine Of New York University Influenza virus vaccines and uses thereof
EP2536425B1 (en) 2010-02-18 2019-06-19 Icahn School of Medicine at Mount Sinai Vaccines for use in the prophylaxis and treatment of influenza virus disease
US9708373B2 (en) 2010-03-30 2017-07-18 Icahn School Of Medicine At Mount Sinai Influenza virus vaccine and uses thereof
CN104185476A (zh) 2011-09-20 2014-12-03 西奈山医学院 流感病毒疫苗及其应用
WO2013079473A1 (en) 2011-11-28 2013-06-06 Crucell Holland B.V. Influenza virus vaccines and uses thereof
WO2013177444A2 (en) * 2012-05-23 2013-11-28 The Board Of Trustees Of The Leland Stanford Junior University Influenza vaccine constructs
WO2014099931A1 (en) 2012-12-18 2014-06-26 Icahn School Of Medicine At Mount Sinai Influenza virus vaccines and uses thereof
US9908930B2 (en) 2013-03-14 2018-03-06 Icahn School Of Medicine At Mount Sinai Antibodies against influenza virus hemagglutinin and uses thereof
SG11201509663PA (en) * 2013-05-30 2015-12-30 Crucell Holland Bv Influenza virus vaccines and uses thereof
WO2015020913A2 (en) 2013-08-03 2015-02-12 Marshall Christopher Patrick Influenza hemagglutinin proteins and methods of thereof
US10344058B2 (en) 2014-05-01 2019-07-09 Indian Institute Of Science Polypeptides for generating anti-influenza antibodies and uses thereof
ZA201608812B (en) 2014-06-26 2019-08-28 Janssen Vaccines & Prevention Bv Antibodies and antigen-binding fragments that specifically bind to microtubule-associated protein tau
US10301379B2 (en) 2014-06-26 2019-05-28 Janssen Vaccines & Prevention B.V. Antibodies and antigen-binding fragments that specifically bind to microtubule-associated protein tau
SG11201610443WA (en) * 2014-07-10 2017-01-27 Janssen Vaccines & Prevention Bv Influenza virus vaccines and uses thereof
PE20170291A1 (es) * 2014-07-10 2017-03-26 Janssen Vaccines And Prevention B V Vacunas contra virus de influenza y usos de las mismas
IL249704B (en) * 2014-07-10 2021-03-25 Janssen Vaccines & Prevention Bv Influenza virus vaccines and their uses
US10736956B2 (en) 2015-01-23 2020-08-11 Icahn School Of Medicine At Mount Sinai Influenza virus vaccination regimens
EP3294753A1 (en) * 2015-05-11 2018-03-21 Janssen Vaccines & Prevention B.V. Influenza virus neutralizing peptidomimetic compounds
WO2017037196A1 (en) * 2015-09-02 2017-03-09 Janssen Vaccines & Prevention B.V. Stabilized viral class i fusion proteins
EP3471767A4 (en) 2016-06-15 2020-01-15 Icahn School of Medicine at Mount Sinai INFLUENZA VIRUS HEMAGGLUTININS AND USES THEREOF
SG11201901790YA (en) 2016-09-02 2019-03-28 The Usa As Represented By The Secretary Stabilized group 2 influenza hemagglutinin stem region trimers and uses thereof
WO2018053178A1 (en) * 2016-09-16 2018-03-22 Vaccitech, Inc. Compositions and methods for vaccination against influenza
EP3528827A4 (en) * 2016-10-21 2020-11-04 Merck Sharp & Dohme Corp. INFLUENZA HEMAGGLUTININ PROTEIN Vaccines
WO2018187706A2 (en) 2017-04-07 2018-10-11 Icahn School Of Medicine At Mount Sinai Anti-influenza b virus neuraminidase antibodies and uses thereof
CA3076263C (en) * 2017-11-22 2023-12-19 Her Majesty the Queen in the Right of Canada as represented by the Minister of Health Synthetic hemagglutinin as universal vaccine against infection by type b influenza viruses (ibv)
EP3730620A4 (en) * 2017-12-21 2022-01-05 Green Biomed, Inc. CROSS-IMMUNIZATION ANTIGENIC VACCINE AND PROCESS FOR PREPARATION
HUE059545T2 (hu) 2018-01-23 2022-11-28 Janssen Vaccines & Prevention Bv Influenzavírus-vakcinák és alkalmazásaik
SG11202012398UA (en) 2018-06-27 2021-01-28 Medicago Inc Influenza virus hemagglutinin mutants
CN113597428A (zh) * 2019-04-25 2021-11-02 扬森疫苗与预防公司 重组流感抗原
US20230250135A1 (en) 2019-09-05 2023-08-10 Janssen Vaccines & Prevention B.V. Influenza virus vaccines and uses thereof
JP2022553258A (ja) * 2019-10-15 2022-12-22 ヤンセン ファッシンズ アンド プリベンション ベーフェー インフルエンザウイルスワクチン及びその使用
US20230310575A1 (en) * 2020-09-02 2023-10-05 St. Jude Children's Research Hospital, Inc. Hemagglutinin Modifications for Improved Influenza Vaccine Production
MX2023002674A (es) 2020-09-07 2023-04-03 Intervet Int Bv Vacuna del tallo de ha para blancos positivos a anticuerpos ha.
BR112023027401A2 (pt) * 2021-06-28 2024-03-12 Glaxosmithkline Biologicals Sa Antígenos do vírus influenza
WO2024038382A1 (en) * 2022-08-16 2024-02-22 Seqirus Inc. Modified influenza viruses
CN116589566A (zh) * 2022-11-18 2023-08-15 昆明医科大学第一附属医院 一种HIV-1中和抗体的改造重组单克隆IgM抗体及其应用
CN116874607A (zh) * 2023-06-09 2023-10-13 山西高等创新研究院 一种h9亚型禽流感重组嵌合疫苗及其制备方法
CN116947982B (zh) * 2023-07-12 2024-05-14 吉林大学 三条优势表位肽序列及其在流感病毒疫苗的应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010117786A1 (en) * 2009-03-30 2010-10-14 Mount Sinai School Of Medicine Of New York University Influenza virus vaccines and uses thereof

Family Cites Families (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5057540A (en) 1987-05-29 1991-10-15 Cambridge Biotech Corporation Saponin adjuvant
NZ230747A (en) 1988-09-30 1992-05-26 Bror Morein Immunomodulating matrix comprising a complex of at least one lipid and at least one saponin; certain glycosylated triterpenoid saponins derived from quillaja saponaria molina
JPH0832638B2 (ja) 1989-05-25 1996-03-29 カイロン コーポレイション サブミクロン油滴乳剤を含んで成るアジュバント製剤
JP3037554B2 (ja) * 1993-04-20 2000-04-24 寳酒造株式会社 免疫原性人工ポリペプチド
AUPM873294A0 (en) 1994-10-12 1994-11-03 Csl Limited Saponin preparations and use thereof in iscoms
US6670188B1 (en) 1998-04-24 2003-12-30 Crucell Holland B.V. Packaging systems for human recombinant adenovirus to be used in gene therapy
US6413776B1 (en) 1998-06-12 2002-07-02 Galapagos Geonomics N.V. High throughput screening of gene function using adenoviral libraries for functional genomics applications
US20030017138A1 (en) 1998-07-08 2003-01-23 Menzo Havenga Chimeric adenoviruses
US6248780B1 (en) 1998-10-01 2001-06-19 Duquesne University Of The Holy Ghost Compounds for the treatment of estrogen-dependent illnesses and methods for making and using the same
US6929946B1 (en) 1998-11-20 2005-08-16 Crucell Holland B.V. Gene delivery vectors provided with a tissue tropism for smooth muscle cells, and/or endothelial cells
US6869936B1 (en) 1999-03-04 2005-03-22 Crucell Holland B.V. Means and methods for fibroblast-like or macrophage-like cell transduction
US7604960B2 (en) 1999-04-15 2009-10-20 Crucell Holland B.V. Transient protein expression methods
US6492169B1 (en) 1999-05-18 2002-12-10 Crucell Holland, B.V. Complementing cell lines
US6913922B1 (en) 1999-05-18 2005-07-05 Crucell Holland B.V. Serotype of adenovirus and uses thereof
AU9434801A (en) 2000-08-10 2002-02-18 Crucell Holland Bv Gene delivery vectors with cell type specificity for primary human chondrocytes
US6905678B2 (en) 2001-07-07 2005-06-14 Crucell Holland B.V. Gene delivery vectors with cell type specificity for mesenchymal stem cells
ES2335657T3 (es) 2002-04-25 2010-03-31 Crucell Holland B.V. Medios y metodos para la produccion de vectores de adenovirus.
CN100374574C (zh) 2002-04-25 2008-03-12 克鲁塞尔荷兰公司 稳定的腺病毒载体及其增殖方法
SE0202110D0 (sv) 2002-07-05 2002-07-05 Isconova Ab Iscom preparation and use thereof
EP1553983A2 (en) 2002-10-23 2005-07-20 Crucell Holland B.V. New settings for recombinant adenoviral-based vaccines
US20080153083A1 (en) 2003-10-23 2008-06-26 Crucell Holland B.V. Settings for recombinant adenoviral-based vaccines
US20050221493A1 (en) 2002-12-04 2005-10-06 Crucell Holland B.V. Recombinant virus production for the manufacturing of vaccines
SE0301998D0 (sv) 2003-07-07 2003-07-07 Isconova Ab Quil A fraction with low toxicity and use thereof
BRPI0414670A (pt) 2003-10-02 2006-11-21 Crucell Holland Bv método para preparar uma célula, célula, métodos para fornecer uma célula e para gerar uma batelada de adenovìrus recombinante, molécula recombinante, conjunto de pelo menos duas moléculas de ácido nucleico, e, sistema de empacotamento
WO2006053871A2 (en) 2004-11-16 2006-05-26 Crucell Holland B.V. Multivalent vaccines comprising recombinant viral vectors
EP2059532B1 (en) 2006-09-07 2012-12-26 Crucell Holland B.V. Human binding molecules capable of neutralizing influenza virus h5n1 and uses thereof
BRPI1012749B1 (pt) 2009-05-11 2022-01-11 Janssen Vaccines & Prevention B.V. Anticorpo monoclonal humano, seu uso e seu método de produção, imunoconjugado, e composição farmacêutica
US9708373B2 (en) * 2010-03-30 2017-07-18 Icahn School Of Medicine At Mount Sinai Influenza virus vaccine and uses thereof
MX354752B (es) 2010-09-27 2018-03-20 Janssen Vaccines & Prevention Bv Regimen de vacunacion de sensibilizacion y refuerzo heterologo contra malaria.
EP2731967B1 (en) 2011-07-14 2016-10-12 Janssen Vaccines & Prevention B.V. Human binding molecules capable of neutralizing influenza a viruses of phylogenetic group 1 and phylogenetic group 2 and influenza b viruses
US20130122038A1 (en) 2011-11-14 2013-05-16 The United States Of America As Represented By The Secretary Of The Department Heterologous prime-boost immunization using measles virus-based vaccines
WO2013079473A1 (en) 2011-11-28 2013-06-06 Crucell Holland B.V. Influenza virus vaccines and uses thereof
US20130236494A1 (en) 2012-03-06 2013-09-12 Crucell Holland B.V. Vaccination against influenza
CA2865594C (en) 2012-03-08 2021-07-27 Crucell Holland B.V. Human binding molecules capable of binding to and neutralizing influenza b viruses and uses thereof
US9125870B2 (en) 2012-03-22 2015-09-08 Crucell Holland B.V. Vaccine against RSV
CN104662041A (zh) 2012-09-27 2015-05-27 克鲁塞尔荷兰公司 能够结合到并且中和b型肝炎病毒的人类结合分子及其用途
SG11201509663PA (en) 2013-05-30 2015-12-30 Crucell Holland Bv Influenza virus vaccines and uses thereof
PE20170291A1 (es) 2014-07-10 2017-03-26 Janssen Vaccines And Prevention B V Vacunas contra virus de influenza y usos de las mismas
SG11201610443WA (en) 2014-07-10 2017-01-27 Janssen Vaccines & Prevention Bv Influenza virus vaccines and uses thereof

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010117786A1 (en) * 2009-03-30 2010-10-14 Mount Sinai School Of Medicine Of New York University Influenza virus vaccines and uses thereof

Non-Patent Citations (10)

* Cited by examiner, † Cited by third party
Title
BIANCHI ELISABETTA ET AL: "Universal influenza B vaccine based on the maturational cleavage site of the hemagglutinin precursor", JOURNAL OF VIROLOGY., THE AMERICAN SOCIETY FOR MICROBIOLOGY., US, vol. 79, no. 12, 1 June 2005 (2005-06-01), US, pages 7380 - 7388, XP002445847, ISSN: 0022-538X, DOI: 10.1128/JVI.79.12.7380-7388.2005 *
ECKERT DEBRA M ,KAY MICHAEL S: "Stalking influenza.", PNAS, PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES, vol. 107, no. 31, 3 August 2010 (2010-08-03), pages 13563 - 13564, XP002675045, ISSN: 1091-6490, DOI: 10.1073/PNAS.1008672107 *
GAYATHRI BOMMAKANTI, MICHAEL P. CITRON, ROBERT W. HEPLER, CHERYL CALLAHAN, GWENDOLYN J. HEIDECKER, TARIQ AHMAD NAJAR, XIANGHAN LU,: "Design of an HA2-based Escherichia coli expressed influenza immunogen that protects mice from pathogenic challenge.", PNAS, PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES, vol. 107, no. 31, 3 August 2010 (2010-08-03), pages 13701 - 13706, XP002675041, ISSN: 1091-6490, DOI: 10.1073/PNAS.1007465107 *
GAYATHRI BOMMAKANTI, MICHAEL P. CITRON, ROBERT W. HEPLER, CHERYL CALLAHAN, GWENDOLYN J. HEIDECKER, TARIQ AHMAD NAJAR, XIANGHAN LU,: "Supporting Information. Bommakanti et al. 10.1073/pnas.1007465107", PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES (PNAS), US, vol. 107, no. 31, 3 August 2010 (2010-08-03), US, pages 1 - 6, XP002675046, ISSN: 0027-8424, DOI: 10.1073/PNAS.1007465107 *
JOHN STEEL, ANICE C. LOWEN, TAIA T. WANG , MARK YONDOLA, QINSHAN GAO , KESTER HAYE , ADOLFO GARC�A-SASTRE AND PETER PALESE: "Influenza Virus Vaccine Based on the Conserved Hemagglutinin Stalk Domain", MBIO, AMERICAN SOCIETY FOR MICROBIOLOGY, US, vol. 1, no. 1, 18 May 2010 (2010-05-18), US, pages e00018 - e00018-10-10, XP002675042, ISSN: 2150-7511, DOI: 10.1128/mbio.00018-10 *
S.M. KANG; J.M. SONG; R.W. COMPANS;: "Novel vaccines against influenza viruses", VIRUS RESEARCH, AMSTERDAM, NL, vol. 162, no. 1, NL, pages 31 - 38, XP028115824, ISSN: 0168-1702, DOI: 10.1016/j.virusres.2011.09.037 *
SAGAWA H, OHSHIMA A, KATO I, OKUNO Y, ISEGAWA Y: "The immunological activity of a deletion mutant of influenza virus haemagglutinin lacking the globular region", JOURNAL OF GENERAL VIROLOGY., SOCIETY FOR GENERAL MICROBIOLOGY, SPENCERS WOOD., GB, vol. 77, no. 7, 1 January 1996 (1996-01-01), GB, pages 1483 - 1487, XP002675043, ISSN: 0022-1317, DOI: 10.1099/0022-1317-77-7-1483 *
STEEL J, LOWEN A C, PENA L, ANGEL M, SOL�RZANO A, ALBRECHT R, PEREZ D R, GARC�A-SASTRE A, PALESE P.: "Live Attenuated Influenza Viruses Containing NS1 Truncations as Vaccine Candidates against H5N1 Highly Pathogenic Avian Influenza", JOURNAL OF VIROLOGY., THE AMERICAN SOCIETY FOR MICROBIOLOGY., US, vol. 83, no. 4, 1 February 2009 (2009-02-01), US, pages 1742 - 1753, XP002692248, ISSN: 0022-538X, DOI: 10.1128/JVI.01920-08 *
TAIA T. WANG, GENE S. TAN, RONG HAI, NATALIE PICA, LILY NGAI, DAMIAN C. EKIERT, IAN A. WILSON, ADOLFO GARC�A-SASTRE, THOMAS M. MOR: "Vaccination with a synthetic peptide from the influenza virus hemagglutinin provides protection against distinct viral subtypes.", PNAS, PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES, vol. 107, no. 44, 2 November 2010 (2010-11-02), pages 18979 - 18984, XP002675044, ISSN: 1091-6490, DOI: 10.1073/PNAS.1013387107 *
WILSON I A, SKEHEL J J, WILEY D C: "Structure of the haemagglutinin membrane glycoprotein of influenza virus at 3 A resolution.", NATURE, ¬MACMILLAN JOURNALS LTD., ETC.|, LONDON, vol. 289, no. 5796, 29 January 1981 (1981-01-29), London, pages 366 - 373, XP002689324, ISSN: 0028-0836, DOI: 10.1038/289366a0 *

Also Published As

Publication number Publication date
CA2857087A1 (en) 2013-06-06
AU2012343981B2 (en) 2017-09-07
US9452211B2 (en) 2016-09-27
BR112014012681A8 (pt) 2017-06-20
EA201491051A1 (ru) 2015-04-30
EP2785372B1 (en) 2019-06-19
AR089005A1 (es) 2014-07-23
MY170927A (en) 2019-09-19
CN104066446B (zh) 2017-10-03
US20160355553A1 (en) 2016-12-08
IN2014CN04742A (ru) 2015-09-18
PH12014501118B1 (en) 2014-08-04
US20160362455A1 (en) 2016-12-15
BR112014012681A2 (pt) 2017-06-13
IL232780A0 (en) 2014-07-31
IL232780A (en) 2017-09-28
EP3566714A1 (en) 2019-11-13
CA2857087C (en) 2021-05-25
JP6294828B2 (ja) 2018-03-14
CN104066446A (zh) 2014-09-24
WO2013079473A1 (en) 2013-06-06
MX357009B (es) 2018-06-22
AU2012343981A1 (en) 2014-07-10
NZ625973A (en) 2016-09-30
MX2014006396A (es) 2014-07-22
SG11201402633UA (en) 2014-09-26
KR20140099515A (ko) 2014-08-12
TW201329101A (zh) 2013-07-16
PH12014501118A1 (en) 2014-08-04
JP2015502353A (ja) 2015-01-22
TWI618715B (zh) 2018-03-21
ZA201404797B (en) 2022-03-30
KR101983989B1 (ko) 2019-05-31
EP2785372A1 (en) 2014-10-08
US20140357845A1 (en) 2014-12-04
US9969778B2 (en) 2018-05-15
HK1199211A1 (en) 2015-06-26

Similar Documents

Publication Publication Date Title
EA033386B1 (ru) Рекомбинантные иммуногенные полипептиды стеблевого домена гемагглютинина вируса гриппа а и их применение
ES2563646T3 (es) Composiciones y métodos relacionados con variantes de la proteína A (SpA)
PH12015502612B1 (en) Influenza virus vaccines and uses thereof
CY1122824T1 (el) Πρωτεϊνες συντηξης και εμβολια συνδυασμου
MX340735B (es) Proteinas multimericas recombinantes de la influenza.
MY161773A (en) Amylin analogues and pharmaceutical compositions thereof
CL2012000119A1 (es) Polipeptido f de virus respiratorio sincicial recombinante, composicion inmunogenica que lo comprende, uso para la preparacion de un medicamento para la profilaxis contra dicho virus.
CY1119916T1 (el) Ανοσογονικη συνθεση
WO2015020913A3 (en) Influenza hemagglutinin proteins and methods of thereof
UA118167C2 (uk) Пептид та його застосування
IN2014DN07399A (ru)
IN2014DN05695A (ru)
IN2014DN05805A (ru)
MX2016011394A (es) Moleculas de andamiaje a base de fibronectina estabilizada.
AU2011280259A8 (en) Influenza vaccine
AR120721A2 (es) Péptidos y composiciones para el tratamiento de daño articular
BR112017014737A2 (pt) formulação de peptídeos inibidores de mk2
WO2015107363A3 (en) Mycobacterial antigen composition
CO2017012675A2 (es) Péptidos lipidados resistentes a proteasas
IN2015DN03070A (ru)
BR112018072968A2 (pt) peptídeos monolipidados resistentes às proteases
MX2015002279A (es) Peptido pntx(19) sintético, composición farmacéutica.y uso.
EA201690966A1 (ru) Новое соединение для лечения тяжелой гипогликемии
EA201590431A1 (ru) Пшеница с новыми аллелями rht-b1
MX2023008256A (es) Modificacion de polipeptidos de hemaglutinina de influenza transformados por ingenieria genetica.

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM AZ KZ KG TJ TM